CPPD can present in several ways:

• Sudden painful attacks: A joint becomes painful, swollen, warm, and sometimes red over hours.

• Chronic joint pain: Ongoing discomfort, stiffness, or swelling that can resemble osteoarthritis or rheumatoid arthritis.

• No symptoms: Calcium deposits may be visible on an X-ray without causing pain.

• Reduced mobility: Repeated inflammation can make bending or moving an affected joint difficult.

The knee is one of the most frequently affected joints, although CPPD can occur in multiple joints.

A key point: CPPD-related calcification does not always cause pain or disability, and calcification around a tendon is not necessarily caused by CPPD.

Calcium pyrophosphate deposition disease (CPPD) can involve tendons, ligaments, and other structures in and around joints. Crystal deposits and associated inflammation may cause pain, tenderness, swelling, and restricted movement, sometimes producing symptoms similar to tendinitis (tendon inflammation).

CPPD can affect structures around the shoulder, including the rotator cuff, as well as tendons and other soft tissues around the ankle and foot, including the Achilles tendon. The wrists, knees, and pelvis may also be affected. The location and severity of symptoms vary from person to person, and extensive involvement can significantly impair mobility and daily activities.

However, calcification of tendons and other soft tissues can have causes other than CPPD. Clinical assessment and appropriate imaging or crystal analysis may be needed to establish the underlying cause.

Calcium pyrophosphate deposition can cause joints to become hot, intensely painful, red, and swollen in an “attack” that is similar to a disease called gout. This can also be confused with an infection in the joint.

In calcium pyrophosphate deposition disorder crystals of calcium pyrophosphate form inside a joint, an event that triggers the immune system to attack.

Gout is also caused by a buildup of crystals inside a joint, but they are made of uric acid instead, so its causes and treatments are different. This type of calcium pyrophosphate deposition disorder is also called pseudogout.

Calcium pyrophosphate deposition disease (CPPD) can resemble osteoarthritis because both conditions can cause joint pain, stiffness, swelling, and reduced mobility. CPPD frequently affects joints that are also commonly affected by osteoarthritis, including the knees and certain joints of the hands.

However, CPPD can also affect joints and joint regions that are less typical of primary osteoarthritis, including the wrists, elbows, shoulders, and pelvis. It may also occur alongside osteoarthritis, making diagnosis more challenging.

When osteoarthritis-like symptoms occur in an unusual joint distribution, or when imaging reveals cartilage calcification (chondrocalcinosis), CPPD should be considered as a possible diagnosis. However, these findings alone do not confirm CPPD. Diagnosis may require clinical assessment, appropriate imaging, and, in some cases, examination of joint fluid for calcium pyrophosphate crystals.

Calcium pyrophosphate deposition disease (CPPD) can affect the metacarpophalangeal (MCP) joints, where the fingers meet the hands. This can cause pain, swelling, stiffness, and reduced hand function, resembling rheumatoid arthritis (RA).

X-rays can help distinguish CPPD from rheumatoid arthritis. CPPD may produce cartilage calcification (chondrocalcinosis), osteoarthritis-like changes, and characteristic patterns of joint involvement. Rheumatoid arthritis, by contrast, may cause joint erosions and other inflammatory changes. However, early rheumatoid arthritis can have normal X-rays, and the two conditions can sometimes coexist. Additional investigations, including blood tests and joint-fluid analysis when appropriate, may be needed to establish the diagnosis.

CPPD can also be associated with certain metabolic conditions, including hereditary hemochromatosis, a disorder that causes excessive iron accumulation in the body. Hemochromatosis can affect the MCP joints and produce distinctive changes on X-rays. When CPPD occurs at an unusually young age or has a characteristic pattern of hand involvement, clinicians may consider testing for iron overload and other metabolic abnormalities.

Calcium pyrophosphate deposition disease (CPPD) can be associated with certain underlying medical conditions that may contribute to crystal deposition or cause additional symptoms. These include:

• Hypothyroidism: An underactive thyroid gland that produces insufficient thyroid hormones.
• Hyperparathyroidism: Overactivity of the parathyroid glands, which can disrupt calcium regulation in the body.
• Hypomagnesemia: An abnormally low level of magnesium in the blood, which can contribute to calcium pyrophosphate crystal formation.
• Hemochromatosis: A condition in which excessive iron accumulates in the body and can damage joints and other organs.

These conditions do not occur in everyone with CPPD. When CPPD develops at a younger age than usual, affects multiple joints, or presents with other suggestive features, a clinician may recommend blood tests to investigate possible underlying metabolic disorders.

Treating an associated condition is important for overall health, although it does not necessarily eliminate existing calcium pyrophosphate crystals or prevent all future CPPD attacks.

Imaging Tests for Calcium Pyrophosphate Deposition Disease (CPPD)

X-rays: X-rays of affected joints can help identify characteristic features of calcium pyrophosphate deposition disease (CPPD). They may show calcium deposits within cartilage, known as chondrocalcinosis, as well as changes associated with osteoarthritis. Common sites of chondrocalcinosis include the knees and wrists. Deposits may also occur in the shoulders, hips, and pelvis. However, not all CPPD deposits are visible on X-rays, so a normal X-ray does not rule out the condition.

Ultrasound: Ultrasound can help identify calcium pyrophosphate crystal deposits in cartilage and other joint structures, including tendons and ligaments. It can also detect inflammation and fluid around affected joints. Ultrasound is particularly useful for assessing the shoulder and its surrounding structures, including the rotator cuff, when clinically indicated.

Joint Fluid Analysis for Calcium Pyrophosphate Crystals

A sample of fluid from an affected joint can be collected using a procedure called joint aspiration (arthrocentesis) and examined under a microscope for calcium pyrophosphate crystals. This is an important method of diagnosing calcium pyrophosphate deposition disease (CPPD).

Joint fluid analysis can be particularly useful during an acute inflammatory attack, sometimes called pseudogout, when the joint is painful, swollen, and inflamed. The fluid is examined using polarized light microscopy to identify the characteristic crystals.

The sample may also be tested for signs of infection, as a joint infection can cause symptoms similar to a CPPD flare. Identifying crystals supports the diagnosis, but their presence does not exclude a simultaneous infection.

Blood Tests for Calcium Pyrophosphate Deposition Disease (CPPD)

Blood tests to assess other conditions: Blood tests may be used to investigate other causes of joint pain and inflammation, including rheumatoid arthritis and other inflammatory or metabolic conditions. Depending on the symptoms, tests may include rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, inflammatory markers such as C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). These tests help guide the diagnosis but cannot independently confirm or exclude every rheumatic disease.

Tests for conditions associated with CPPD: CPPD can be associated with certain metabolic disorders. When clinically indicated, a healthcare professional may request blood tests to investigate these conditions, including:

• Thyroid function tests: Assess thyroid function and help identify hypothyroidism.
• Parathyroid hormone (PTH) and calcium levels: Help investigate hyperparathyroidism and abnormalities in calcium regulation.
• Iron studies, including ferritin and transferrin saturation: Help identify iron overload associated with hemochromatosis.
• Magnesium levels: Detect hypomagnesemia (abnormally low blood magnesium).
• Other metabolic tests: Phosphate and alkaline phosphatase may be measured when a broader metabolic assessment is appropriate.

These investigations are particularly worth considering when CPPD occurs at a younger age, affects multiple joints, or has other features suggesting an underlying metabolic disorder. Blood tests do not diagnose CPPD directly; the diagnosis is based on the clinical findings and, when appropriate, joint-fluid analysis and imaging.

Genetics is believed to play an important role in the development of ankylosing spondylitis (AS).

Approximately 90% of people with AS carry a gene known as HLA-B27, which is associated with an increased risk of developing the condition. However, having this gene does not mean that a person will inevitably develop AS, as many people who carry HLA-B27 never develop the disease.

Although HLA-B27 is an important genetic risk factor, other genetic and environmental factors are also thought to contribute to the development of AS.

Ankylosing spondylitis (AS) should be diagnosed early and managed effectively to control inflammation, maintain spinal flexibility, and preserve joint mobility. Early treatment can help slow disease progression and reduce the risk of long-term complications, including the fusion of bones in the spine.

Although existing structural damage caused by AS cannot usually be reversed with medication, appropriate treatment can help relieve pain, reduce inflammation, improve mobility, and preserve physical function. Regular follow-up appointments with a rheumatologist are essential, along with completing any recommended blood tests and imaging scans to monitor disease activity and assess treatment effectiveness.

The management of ankylosing spondylitis generally involves two key approaches:

• Physical therapy and exercise: Regular physical activity, physiotherapy, and daily stretching can help reduce stiffness, maintain flexibility, improve posture, and support overall mobility.
• Medication: Medications can help control inflammation, relieve pain, and improve physical function and quality of life.

A summary of the main treatment options available to help manage ankylosing spondylitis and improve patients’ quality of life is provided below.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Nonsteroidal anti-inflammatory drugs (NSAIDs) can help reduce inflammation, pain, and swelling associated with calcium pyrophosphate deposition disease (CPPD). They may be used to manage acute pseudogout attacks and, in selected cases, ongoing symptoms associated with CPPD-related arthritis or inflammation around joints and tendons.

NSAIDs may be particularly useful when several joints are affected or when corticosteroid injections are not practical or appropriate. Depending on the severity and frequency of symptoms, a healthcare professional may recommend short-term treatment or, in selected cases, longer-term use at the lowest effective dose.

Examples include ibuprofen and naproxen. However, NSAIDs are not suitable for everyone. They can increase the risk of stomach ulcers and bleeding, kidney problems, fluid retention, and cardiovascular complications. Older adults and people with kidney disease, heart disease, high blood pressure, or a history of stomach ulcers should consult a healthcare professional before using them regularly.

Medications for Pain Relief

Acetaminophen (paracetamol; Tylenol) is a non-prescription pain reliever that may help manage mild to moderate pain associated with CPPD. However, it does not substantially reduce the inflammation caused by crystal deposits. It may be useful when NSAIDs are unsuitable, although its effectiveness varies.

Acetaminophen is generally well tolerated when taken at the recommended dose, but excessive use can cause serious liver damage. Long-term or regular use should be discussed with a healthcare professional, particularly for people with liver disease or those who consume substantial amounts of alcohol.

Opioid medications may occasionally be considered for severe pain when other treatments are ineffective or unsuitable. However, they are generally not a first-line treatment for CPPD because they do not treat the underlying inflammation and can cause constipation, drowsiness, falls, dependence, and overdose. Their use should be carefully assessed and monitored by a healthcare professional.

A clinician may recommend:

• Joint fluid analysis: Fluid is collected with a needle and examined for calcium pyrophosphate crystals. It can also be tested for infection.

• X-rays: These may show cartilage calcification, called chondrocalcinosis.

• Ultrasound: This can help identify crystal deposits in cartilage and around joints.

• Blood tests: These may check for metabolic conditions or help rule out other causes.

A sudden, hot, swollen joint must be assessed promptly because a joint infection can look very similar to a CPPD flare

There is currently no proven treatment that removes the existing CPP crystals, but symptoms can often be controlled effectively.

The choice of medication depends on kidney function, stomach health, heart conditions, other medications, and the severity of symptoms.

There is no specific diet proven to stopCalcium Pyrophosphate Deposition Disorder . A Mediterranean-style pattern—vegetables and fruit, whole grains, legumes, nuts, fish, and unsaturated fats—is a reasonable approach for overall health. Foods such as tomatoes and bell peppers can be included, but they shouldn’t be considered treatments for AS.

Tomatoes and arthritis

Tomatoes can be a nutritious addition to an arthritis-friendly diet, although they do not cure arthritis or directly reverse joint damage.

• Lycopene: Tomatoes are particularly rich in lycopene, an antioxidant that helps protect cells from oxidative stress. Cooked tomatoes and tomato products can provide especially well-absorbed lycopene.

• Vitamin C: Supports collagen formation and normal connective-tissue function.

• Antioxidants: Tomatoes contain vitamin C, carotenoids, and other plant compounds that contribute to overall antioxidant intake.

• Potential anti-inflammatory effects: Laboratory and observational research suggests that compounds in tomatoes may influence inflammatory pathways, but evidence that eating tomatoes significantly reduces arthritis pain or inflammation in people is still limited.

• Heart health: Tomatoes can contribute to a heart-healthy diet, which is particularly relevant for people with rheumatoid arthritis, because RA is associated with increased cardiovascular risk.

Some people with arthritis report that tomatoes or other nightshade vegetables worsen their symptoms. There isn’t strong scientific evidence that tomatoes generally cause arthritis inflammation or should routinely be avoided. If you consistently notice symptoms after eating a particular food, discussing this pattern with a healthcare professional or dietitian can be more useful than eliminating foods unnecessarily.

For osteoarthritis, tomatoes are best viewed as part of an overall nutritious eating pattern. For rheumatoid arthritis, diet can complement medical treatment but shouldn’t replace disease-modifying medication when it is prescribed.

Calcium pyrophosphate deposition disease (CPPD) can be difficult to diagnose because its symptoms may resemble those of other musculoskeletal conditions, including gout, osteoarthritis, rheumatoid arthritis, and tendinitis. These conditions can cause similar symptoms, such as joint pain, swelling, stiffness, and reduced mobility.

A rheumatologist, a physician who specializes in arthritis and other diseases affecting the joints, muscles, and immune system, can help assess suspected CPPD. However, a primary care physician or another healthcare professional may also begin the diagnostic process.

To investigate CPPD, the clinician will take a detailed medical history and perform a thorough physical examination. Depending on the findings, further investigations may include:

• Joint-fluid analysis: Fluid collected from an affected joint can be examined under a microscope for calcium pyrophosphate crystals. This is an important way to confirm the diagnosis and may also help identify or exclude a joint infection.
• Imaging: X-rays may reveal cartilage calcification (chondrocalcinosis) and joint changes. Ultrasound or other imaging techniques may help identify crystal deposits and assess affected tissues.
• Blood tests: These may help identify associated metabolic conditions, such as abnormal calcium or magnesium levels, hyperparathyroidism, or hemochromatosis, and help evaluate other possible causes of symptoms.

The diagnosis is based on the overall clinical picture and investigation results. No single blood test can diagnose CPPD, and the absence of visible calcification on an X-ray does not necessarily exclude the disease.

Treatment for calcium pyrophosphate deposition disease (CPPD) varies depending on the symptoms, the joints or tissues affected, the severity of inflammation, and the person’s overall health. Although there is currently no established treatment that removes existing calcium pyrophosphate crystals, several medications can help control inflammation, relieve pain, reduce the frequency of attacks, and maintain mobility. With appropriate management, many people with CPPD can continue to lead active and productive lives.

Corticosteroid (Cortisone) Injections

Corticosteroid injections can be effective for reducing pain and inflammation in people experiencing acute pseudogout attacks or inflammation affecting an individual joint. They may also be considered for selected cases of CPPD associated with osteoarthritis-like symptoms or inflammation around tendons and other soft tissues.

When injected into an affected joint, corticosteroids can reduce swelling, tenderness, and pain. Relief may begin within 24–48 hours, although the time to improvement varies. The duration of benefit ranges from days to months, depending on the individual, the affected joint, and the underlying condition.

The frequency of injections should be determined by a healthcare professional. Repeated injections into the same joint are generally limited because of potential adverse effects on cartilage and other tissues. A commonly used guideline is to avoid exceeding three or four injections into the same joint in a year, although the appropriate limit depends on the clinical circumstances.

Oral Corticosteroids

Oral corticosteroids, such as prednisone, may be prescribed for acute CPPD attacks, particularly when several joints are affected or when other treatments are unsuitable. A short course can help control significant inflammation.

In selected patients with frequent or persistent attacks, a clinician may consider low-dose corticosteroid treatment. However, regular long-term use requires careful assessment because it can increase the risk of infections, osteoporosis, diabetes, and other adverse effects.

Colchicine (Colcrys)

Colchicine is a medication used to treat acute CPPD attacks and, in some people, to help prevent recurrent attacks. It is also widely used to treat gout, although gout and CPPD are different crystal-related diseases.

For people who experience repeated pseudogout attacks, a clinician may prescribe a low dose of colchicine on a regular schedule to reduce the frequency of flare-ups. The dose and duration depend on the individual’s symptoms, kidney and liver function, and other medications.

Colchicine should be taken according to the prescribed instructions. Stopping preventive treatment may allow attacks to recur in some people, but stopping colchicine does not itself necessarily trigger an attack. Patients should consult their healthcare professional before changing their treatment.

Colchicine can cause side effects, particularly diarrhoea, nausea, and abdominal discomfort. Serious toxicity can occur if too much is taken or if it interacts with certain medications, so the prescribed dose should never be exceeded.